Close X
Thursday, October 31, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

Tam: variants threatening vaccine progress

Tam: variants threatening vaccine progress
Prime Minister Justin Trudeau reiterated Friday that Canada is on pace to vaccinate all residents who want a vaccine by the end of September.

Tam: variants threatening vaccine progress

Blood clot risk bigger with COVID-19 than vaccines

Blood clot risk bigger with COVID-19 than vaccines
Thrombosis Canada issued an updated statement on the risk of blood clots late Thursday, after the European Medicines Agency released its final report on the risk of blood clots after getting the Oxford-AstraZeneca vaccine.

Blood clot risk bigger with COVID-19 than vaccines

Canada to ratify trade deal with United Kingdom

Canada to ratify trade deal with United Kingdom
The agreement will provide Canadian exporters and businesses with continued preferential access to the U.K. market.

Canada to ratify trade deal with United Kingdom

Conservatives to debate next steps on policy

Conservatives to debate next steps on policy
The party's policy document under scrutiny Friday is supposed to help guide the election platform.

Conservatives to debate next steps on policy

PM slams 'lack of transparency' in China's trial

PM slams 'lack of transparency' in China's trial
Justice Department officials have refused to say much about the case beyond the fact that they continue to seek her extradition to the U.S.

PM slams 'lack of transparency' in China's trial

Trudeau pledges to hold Iran to account

Trudeau pledges to hold Iran to account
A group representing the families is demanding Canada impose sanctions against Iran's Revolutionary Guard to pry out more information on the shootdown.

Trudeau pledges to hold Iran to account